Stockscreener 앱 받기
14.11
0.14%
0.02
시장 영업 전:
14.25
0.14
+0.99%
전일 마감가:
$14.09
열려 있는:
$14.14
하루 거래량:
1.70M
Relative Volume:
0.85
시가총액:
$1.71B
수익:
-
순이익/손실:
$-804.34M
주가수익비율:
-1.4995
EPS:
-9.41
순현금흐름:
$-531.06M
1주 성능:
-2.42%
1개월 성능:
-4.73%
6개월 성능:
-62.22%
1년 성능:
-59.35%
1일 변동 폭
$13.90
$14.54
1주일 범위
$13.90
$15.18
52주 변동 폭
$13.87
$55.70
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
BHVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
14.11 | 1.71B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - Bluefield Daily Telegraph
Biohaven stock hits 52-week low at 14.32 USD By Investing.com - Investing.com India
Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN S - GuruFocus
Biohaven (BHVN) Target Price Lowered by JP Morgan Analyst | BHVN Stock News - GuruFocus
Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN Stock News - GuruFocus
Biohaven price target lowered to $55 from $68 at JPMorgan - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. ... - Bluefield Daily Telegraph
Biohaven Insiders Added US$6.28m Of Stock To Their Holdings - Yahoo Finance
Investigation Underway: Biohaven Ltd. (BHVN)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
New Haven-based bioscience firms Bexorg, Biohaven agree to collaborate - Hartford Business Journal
BHVN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Biohaven Ltd. - ACCESS Newswire
Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research C - GuruFocus
Kalkine : Biohaven Ltd Shift Amid Sector Moves and Earnings Per Share Focus - Kalkine Media
Biohaven, Bexorg Collaborate to Develop CNS Therapies - MarketScreener
Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research Collaboration | BHVN Stock News - GuruFocus
Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development - The Manila Times
Bexorg announces multi-program research collaboration with Biohaven - TipRanks
Bexorg Announces Research Collaboration with Biohaven - GlobeNewswire
Biohaven Ltd. (NYSE:BHVN) Shares Purchased by Parallel Advisors LLC - Defense World
Levi & Korsinsky Investigates Possible Securities Fraud by Biohaven Ltd. (BHVN) - ACCESS Newswire
Fraud Investigation: Levi & Korsinsky Investigates Biohaven Ltd. (BHVN) on Behalf of Shareholders - ACCESS Newswire
Levi & Korsinsky Investigating Whether Biohaven Ltd. (BHVN) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - GlobeNewswire Inc.
Ongoing Biohaven Ltd. (BHVN) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
Biohaven Ltd. Highlights Strategic Focus in Investor Presentation - MSN
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Biohaven Ltd. (BHVN) - ACCESS Newswire
Sector Update: Health Care - marketscreener.com
Biohaven Shares Rise on Drug Pipeline Update With Two Near-Market Candidates - marketscreener.com
Shareholders Alert: Investigation Into Biohaven Ltd. (BHVN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating - TipRanks
Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy” - Insider Monkey
Jim Cramer’s Thoughts on These 10 Stocks - Insider Monkey
Biohaven Lands Major $600 Million Deal With Oberland Capital - Finimize
How To Trade (BHVN) - news.stocktradersdaily.com
Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements - TipRanks
Biohaven stock hits 52-week low at $14.36 amid market challenges By Investing.com - Investing.com South Africa
Morgan Stanley maintains Biohaven stock with $63 target - Investing.com Australia
BHVN Investor Notice: Levi & Korsinsky Investigates Biohaven Ltd. for Securities Law Violations - ACCESS Newswire
Biohaven stock hits 52-week low at $14.36 amid market challenges - Investing.com Nigeria
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target - Investing.com Australia
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target By Investing.com - Investing.com India
Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments - TipRanks
Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Cowen reiterates Buy on Biohaven stock, maintains $75 target By Investing.com - Investing.com South Africa
Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - MarketScreener
Cowen reiterates Buy on Biohaven stock, maintains $75 target - Investing.com
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug - GuruFocus
Biohaven initiates global Phase 2/3 study of BHV-8000 - TipRanks
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus
TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오헤이븐 주식 (BHVN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Car Bruce | Chief Scientific Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
4,750 |
0 |
7,133 |
| Gentile Kimberly | SVP, Clinical Operations |
Jan 05 '25 |
Option Exercise |
0.00 |
3,750 |
0 |
99,719 |
| Clark George C. | VP, Chief Accounting Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
66,168 |
| Buten Matthew | Chief Financial Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
4,250 |
0 |
196,013 |
| Coric Vlad | Chief Executive Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
14,250 |
0 |
1,803,409 |
| CHILDS JOHN W | Director |
Dec 30 '24 |
Buy |
35.94 |
29,000 |
1,042,393 |
2,368,741 |
| CHILDS JOHN W | Director |
Oct 02 '24 |
Buy |
47.50 |
21,052 |
999,970 |
21,052 |
| Coric Vlad | Chief Executive Officer |
Oct 02 '24 |
Buy |
47.50 |
21,052 |
999,970 |
861,942 |
| Bailey Gregory | Director |
Sep 24 '24 |
Buy |
44.19 |
5,000 |
220,966 |
1,620,071 |
| CHILDS JOHN W | Director |
Jul 18 '24 |
Buy |
35.67 |
28,400 |
1,012,983 |
2,339,741 |
0.78%
0.23%
자본화:
|
볼륨(24시간):